Status:
COMPLETED
Functional Lung Imaging With DECT and 4DCT
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The basic premise of this pilot study is to enroll 40 patients over 3 years who have Stage II, III, or IV non-small cell lung cancer and are planned for definitive treatment with concurrent chemoradia...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients have histologic diagnosis of non-small cell lung cancer
- Patients have AJCC stage II, III or IV disease were the plan is to receive definitive concurrent chemoradiation to 60 Gy or higher
- Age \> 18 years of age
- Patients are able to provide informed consent
- No additional lung radiation is planned until after the 2nd CT on this study (i.e. patient does not have a solitary pulmonary nodule or second primary that the plan is to undergo SBRT)
- Patient must have adequate kidney function to receive IV contrast (following institutional policy supplied by radiology). The cutoff level for serum creatinine is 1.6 mg/dL
- Negative urine pregnancy test before every CT scan
- Exclusion criteria:
- Allergy to IV iodine contrast
- Severe claustrophobia
- Further thoracic radiation therapy is planned.
Exclusion
Key Trial Info
Start Date :
January 2 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 5 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04702607
Start Date
January 2 2021
End Date
October 5 2024
Last Update
November 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abamson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104